A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Key Inclusion Criteria:

1. Documented or participant-reported history of moderate to severe birch pollenallergy for at least 2 years with bothersome ocular symptoms during the birch season

2. Positive SPT to birch allergen extract, as described in the protocol

3. Positive allergen specific immunoglobulin E (sIgE) tests for birch and Bet v 1 (≥0.7kUa/L) at screening visit 1

4. Must be able to complete birch screening CACs and meet the criteria, as described inthe protocol

Key Exclusion Criteria:

1. Participation in a prior clinical study and received either REGN5713-5714-5715,REGN5713-5715, or REGN5715 antibodies, as described in the protocol

2. Inability to complete or termination of the screening or confirmatory CACs due to asafety concern (eg, anaphylaxis) per Principal Investigator (PI) judgement

3. Significant and/or severe allergies causing symptoms that are expected to coincideor potentially interfere with the study CAC assessments, as assessed by theinvestigator, as described in the protocol

4. Persistent chronic or recurring acute infection requiring treatment with systemicantibiotics, antivirals, or antifungals, or any untreated respiratory infectionswithin 4 weeks prior to screening visit 1, as described in the protocol

5. The presence of an active ocular infection (bacterial, viral, or fungal) ordiagnosis by a physician within 30 days prior to screening visit 1, as described inthe protocol

Note: Other protocol defined Inclusion/Exclusion criteria apply.